Form 4: Co-Diagnostics Director Reports Stock Transactions

Edward L. Murphy, a Director at Co-Diagnostics, Inc., reported transactions involving restricted stock units and common stock.

Summary

• Edward L. Murphy, a Director at Co-Diagnostics, Inc. (CODX), reported a transaction on May 23, 2026.
• The transaction involved the acquisition of 1,695 shares of Common Stock for $0.00.
• Following this transaction, Mr. Murphy beneficially owns 11,084 shares of Common Stock.
• Additionally, a transaction code 'M' indicates a modification or grant related to 1,695 Restricted Stock Units (RSUs) with a value of $0.00.
• These RSUs are tied to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan.
• The filing also details the vesting schedule for various RSU awards granted on June 12, 2023, April 26, 2024, and August 13, 2025, with vesting commencing every six months starting November 23, 2023, November 23, 2024, and November 23, 2025, respectively.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine insider stock transactions and RSU vesting schedules, typical for executive compensation disclosures, rather than significant strategic or financial performance indicators.

Positives

• Director Edward L. Murphy acquired additional shares of common stock, indicating continued investment in the company.
• The acquisition of shares was at no cost ($0.00), suggesting it was part of an equity incentive plan.
• Details on multiple RSU awards and their vesting schedules provide transparency into executive compensation and long-term incentives.

Future Outlook

The filing details vesting schedules for restricted stock units awarded on June 12, 2023, April 26, 2024, and August 13, 2025, with installments vesting every six months starting November 23, 2023, November 23, 2024, and November 23, 2025, respectively. This indicates a structured approach to long-term executive compensation.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions in the biotechnology and diagnostics sector, providing transparency to investors regarding the holdings and activities of company directors and officers.

Stakeholder Impact

• Shareholders gain insight into director's equity holdings and potential alignment with company performance through RSU vesting.
• Employees may observe executive compensation structures and long-term incentive plans.

Key Dates

Keywords

Co-Diagnostics, CODX, Form 4, SEC Filing, Insider Trading, Stock Transaction, Restricted Stock Units, Director, Beneficial Ownership